VYNDAMAX 61 MG
TAFAMIDIS 61 MG · DIN 02517841 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is VYNDAMAX?
VYNDAMAX 61 MG contains TAFAMIDIS 61 MG. It is listed in the Health Canada Drug Product Database under DIN 02517841, held by PFIZER CANADA ULC, supplied as Capsule for Oral administration. Health Canada currently lists it as marketed, status dated 15-Sep-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VYNDAMAX used for?
VYNDAMAX (tafamidis) is indicated for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis (ATTR-CM), wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02517841 |
|---|---|
| Brand name | VYNDAMAX |
| Generic / active ingredient | TAFAMIDIS 61 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 61 MG |
| Dosage form | Capsule |
| Route of administration | Oral |
| Schedule | PRESCRIPTION |
| ATC code | N07XX08 TAFAMIDIS |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Sep-2021 |
| Original market date | 2021-09-15 00:00:00 |
How is it administered?
The recommended dose of VYNDAMAX (tafamidis) is 61 mg tafamidis (administered as one 61-mg tafamidis capsule) orally once daily. The capsule(s) should be swallowed whole and not crushed or cut. VYNDAMAX may be taken with or without food. If a dose is missed, the patient should take the dose as soon as remembered. If it is almost time for the next dose, the patient should skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose. The dose may be reduced to one capsule of 20 mg VYNDAQEL (tafamidis meglumine) (equivalent to 12.2 mg of tafamidis) if not tolerated.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store VYNDAMAX at room temperature 15°C to 25°C. Keep out of reach and sight of children.
How is it supplied?
VYNDAMAX (tafamidis) 61 mg: reddish brown, opaque, oblong (approximately 21 mm) capsule with "VYN 61" printed in white. Thirty (30) capsules (one-month supply) supplied in a carton of 3 blister cards. Each blister card contains 10 capsules.
Contraindications
VYNDAMAX (tafamidis) is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
VYNDAMAX should not be used during pregnancy. Women of childbearing potential should use appropriate contraception when taking VYNDAMAX and continue to use contraception for one month after stopping treatment. VYNDAMAX is not recommended in organ transplant patients. VYNDAMAX has not been studied in patients with severe hepatic impairment and use is not recommended in these patients. Limited data are available in patients with severe renal impairment (creatinine clearance less than or equal to 30 mL/min). VYNDAMAX should not be used by nursing women.
What can be used instead?
Other Canadian products sharing ATC code N07XX08 TAFAMIDIS. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| VYNDAQEL | 20 MG | CAPSULE | PFIZER CANADA ULC | MARKETED | DIN 02495732 |
Who else supplies TAFAMIDIS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TAFAMIDIS appears in 23 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.